HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jamie L Bingaman-Steele Selected Research

IMM20184, IMM20190, and IMM20253 drug combination

1/2022IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jamie L Bingaman-Steele Research Topics

Disease

1Neoplasms (Cancer)
01/2023
1COVID-19
01/2022
1Infections
01/2022

Drug/Important Bio-Agent (IBA)

1Immune Checkpoint InhibitorsIBA
01/2023
1InterleukinsIBA
01/2023
1ChemokinesIBA
01/2023
1Broadly Neutralizing AntibodiesIBA
01/2022
1SARS-CoV-2 spike proteinIBA
01/2022
1AntibodiesIBA
01/2022
1Antiviral Agents (Antivirals)IBA
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1Combined Antibody TherapeuticsIBA
01/2022
1IMM20184, IMM20190, and IMM20253 drug combinationIBA
01/2022
1N-(2-cyanoethylene)urea (BA 1)IBA
01/2022
1N-methyl-valyl-amiclenomycin (BA 2)IBA
01/2022